Literature DB >> 29667275

Clinicopathological significance of miR-26, miR-107, miR-125b, and miR-203 in head and neck carcinomas.

W A González-Arriagada1, P Olivero2, B Rodríguez2, C Lozano-Burgos3, C E de Oliveira4,5, R D Coletta5.   

Abstract

OBJECTIVES: MicroRNAs play a role in the development and progression of head and neck squamous cell carcinomas (HNSCC). Our aim was to study the expression of miR-26, miR-107, miR-125b, and miR-203 in primary HNSCC with and without lymph node metastasis and their clinicopathological significance.
MATERIALS AND METHODS: The expression of microRNAs in primary HNSCC with lymph node metastasis (n = 16) and their matched lymph node, as well as primary tumors without metastasis (n = 16), were determined by quantitative RT-PCR and analyzed with clinicopathological features and survival.
RESULTS: The expression levels of miR-26 (p < .05) and miR-125b (p < .01) were higher in metastatic primary HNSCC, while levels of miR-203 (p < .01) were lower. The expression of the microRNAs was associated with clinicopathological features, including miR-26 high expression and N stage (p = .04), poor differentiation (p = .005) and recurrence (p = .007), miR-125b high expression and N stage (p = .0005) and death (p = .02), and low levels of miR-203 and N stage (p = .04). The high expression of miR-26 was associated with shortened disease-free survival, and high miR-125b expression was an independent risk factor for poor disease-specific survival.
CONCLUSIONS: These findings suggest that miR-26 and miR-125b may be associated with the progression and metastasis of HNSCC and that miR-203 is associated with a more favorable prognosis.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  head and neck cancer; lymphatic metastasis; microRNA; neoplasms; outcome; prognosis

Mesh:

Substances:

Year:  2018        PMID: 29667275     DOI: 10.1111/odi.12872

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  6 in total

1.  miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A.

Authors:  Yi-Fen Chen; Yun-Yen Wei; Cheng-Chieh Yang; Chung-Ji Liu; Li-Yin Yeh; Chung-Hsien Chou; Kuo-Wei Chang; Shu-Chun Lin
Journal:  Redox Biol       Date:  2019-02-13       Impact factor: 11.799

2.  Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis.

Authors:  Chellan Kumarasamy; Madurantakam Royam Madhav; Shanthi Sabarimurugan; Sunil Krishnan; Siddhartha Baxi; Ajay Gupta; K M Gothandam; Rama Jayaraj
Journal:  Cells       Date:  2019-07-25       Impact factor: 6.600

Review 3.  Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.

Authors:  Takashi Takeuchi; Hiromichi Kawasaki; Amalia Luce; Alessia Maria Cossu; Gabriella Misso; Marianna Scrima; Marco Bocchetti; Filippo Ricciardiello; Michele Caraglia; Silvia Zappavigna
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

4.  Integrated analysis of deregulation microRNA expression in head and neck squamous cell carcinoma.

Authors:  Cheng-Lin Qi; Jian-Fei Sheng; Mao-Ling Huang; You Zou; Yong-Ping Wang; Fei Wang; Feng Zeng; Qing-Quan Hua; Shi-Ming Chen
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.889

Review 5.  Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck.

Authors:  Razvan Iacob; Matei Mandea; Speranta Iacob; Catalina Pietrosanu; Doru Paul; Razvan Hainarosie; Cristian Gheorghe
Journal:  Front Med (Lausanne)       Date:  2022-04-29

Review 6.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.